Pfizer extends partnership with CytoReason to use AI for drug discovery

Pfizer is extending its partnership with medtech company CytoReason to use CytoReason's artificial intelligence in the drug discovery process.

As part of the partnership, Pfizer will make a $20 million investment and have options to license CytoReason's platform and disease models. The agreement is worth up to $110 million over the next five years, according to the Sept. 20 Pfizer news release.

Pfizer has used CytoReason's platform to research over 20 diseases. 

"We're pleased to expand our strategic collaboration with CytoReason," Pfizer's chief scientific officer and president Mikael Dolsten said. "We look forward to continuing our work with the company's leading scientists and to leveraging its cutting-edge platform. CytoReason's biological data allows us to gain deeper insight into the best drug development pathways for patients, resulting in more informed decisions that are timely and cost-effective."

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars